Tenax Therapeutics, Inc.TENXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P51
Within normal range
vs 2Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.05% |
| Q3 2025 | 68.73% |
| Q2 2025 | 7.71% |
| Q1 2025 | 23.71% |
| Q4 2024 | 47.61% |
| Q3 2024 | 33.74% |
| Q2 2024 | -13.04% |
| Q1 2024 | 57.48% |
| Q4 2023 | 59.43% |
| Q3 2023 | 438.57% |
| Q2 2023 | -25.53% |
| Q1 2023 | -76.58% |
| Q4 2022 | -26.32% |
| Q3 2022 | 1.03% |
| Q2 2022 | 29.42% |
| Q1 2022 | 28.65% |
| Q4 2021 | -21.23% |
| Q3 2021 | 67.68% |
| Q2 2021 | -96.90% |
| Q1 2021 | 2411.46% |
| Q4 2020 | -15.34% |
| Q3 2020 | -17.45% |
| Q2 2020 | -5.04% |
| Q1 2020 | -5.60% |
| Q4 2019 | 55.09% |
| Q3 2019 | 41.24% |
| Q2 2019 | 34.49% |
| Q1 2019 | -4.77% |
| Q4 2018 | 39.79% |
| Q3 2018 | 16.54% |
| Q2 2018 | 431.08% |
| Q1 2018 | 5838.30% |
| Q4 2017 | -100.40% |
| Q3 2017 | -79.23% |
| Q2 2017 | -40.39% |
| Q1 2017 | -18.91% |
| Q4 2016 | -21.79% |
| Q3 2016 | -5.74% |
| Q2 2016 | -12.98% |
| Q1 2016 | -12.73% |